ResMed (NYSE: RMD) reported Q1 EPS of $0.58, in-line with the analyst estimate of $0.58. Revenue for the quarter came in at $380.4 million versus the consensus estimate of $375 million.

For earnings history and earnings-related data on ResMed (RMD) click here.